Browsing by Author Brady, Ben

Jump to: 0-9 A B C D E F G H I J K L M N O P Q R S T U V W X Y Z
or enter first few letters:  
Showing results 1 to 3 of 3
Issue DateTitleAuthor(s)Citation
2009Clinical and Biological Efficacy of Recombinant Human Interleukin-21 in Patients with Stage IV Malignant Melanoma without Prior Treatment: A Phase IIa TrialKefford, Richard (Rick); Brady, Ben; Cebon, Jonathon; Davis, Ian; Hansen, Lasse T.; Lundsgaard, Dorthe; Millward, Michael; Mouritzen, Ulrik; Skak, Kresten; Skrumsager, Birte K.; Western Clinical School: Westmead Millennium InstituteClinical and Biological Efficacy of Recombinant Human Interleukin-21 in Patients with Stage IV Malignant Melanoma without Prior Treatment: A Phase IIa Trial, Clinical Cancer Research, vol.15, 6,pp 2123-2129
2015Nivolumab in Previously Untreated Melanoma without BRAF MutationLong, Georgina; Brady, Ben; Dutriaux, Caroline; et al, Various; Hassel, Jessica; Hernberg, Micaela; Kalinka-Warzocha, Ewa; Maio, Michele; McNeil, Catriona; Mortier, Laurent; Robert, Caroline; Rutkowski, Piotr; Savage, Kerry; Central Clinical School: The Sydney Cancer CentreNivolumab in Previously Untreated Melanoma without BRAF Mutation, The New England Journal of Medicine, vol.372, 4, 2015,pp 320-330
2010A randomized, double-blind, placebo-controlled study of high-dose bosentan in patients with stage IV metastatic melanoma receiving first-line dacarbazine chemotherapyKefford, Richard (Rick); Ballmer, Andrea; Brady, Ben; Clingan, Philip R.; Hersey, Peter; Morganti, Adele; Western Clinical School: Westmead Millennium InstituteA randomized, double-blind, placebo-controlled study of high-dose bosentan in patients with stage IV metastatic melanoma receiving first-line dacarbazine chemotherapy, Molecular Cancer, vol.9, 69, 2010,pp 69-1-69-9